Drug Profile

Cemsidomide - C4 Therapeutics

Alternative Names: CFT 7455

Latest Information Update: 15 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator C4 Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

07 May 2025 C4T Therapeutics expects to receive US FDA feedback on registrational development by mid-year 2025
07 May 2025 Updated efficacy and adverse events data from a phase I/II trial in Multiple myeloma released by C4 Therapeutics
27 Feb 2025 Efficacy and adverse events data from a phase-I/II trial in Multiple myeloma released by C4 Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com